Tamiflu (verum) — Competitive Intelligence Brief

Tamiflu (verum) (Tamiflu (verum)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase inhibitor. Area: Infectious Disease / Virology.

marketed Neuraminidase inhibitor Influenza neuraminidase Infectious Disease / Virology Small molecule

Target snapshot

Tamiflu (verum) (Tamiflu (verum)) — National Institute for Public Health and the Environment (RIVM). Tamiflu inhibits neuraminidase, an enzyme on the surface of influenza viruses, preventing viral release from infected cells and reducing viral spread.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamiflu (verum) TARGET	Tamiflu (verum)	National Institute for Public Health and the Environment (RIVM)	marketed	Neuraminidase inhibitor	Influenza neuraminidase
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir(oral)	Oseltamivir(oral)	Guangdong Raynovent Biotech Co., Ltd	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Tamiflu®	Tamiflu®	Genuine Research Center, Egypt	marketed	Neuraminidase inhibitor	Influenza neuraminidase
zanamivir for inhalation	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir Phosphate For Oral Suspension	Oseltamivir Phosphate For Oral Suspension	The Affiliated Hospital of Qingdao University	marketed	Neuraminidase inhibitor	Influenza neuraminidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase inhibitor class)

1. University of Oxford · 2 drugs in this class
2. GlaxoSmithKline · 2 drugs in this class
3. Guangdong Raynovent Biotech Co., Ltd · 2 drugs in this class
4. UMC Utrecht · 2 drugs in this class
5. Genuine Research Center, Egypt · 1 drug in this class
6. The First Affiliated Hospital of Guangzhou Medical University · 1 drug in this class
7. China Academy of Chinese Medical Sciences · 1 drug in this class
8. Hoffmann-La Roche · 1 drug in this class
9. National Institute for Public Health and the Environment (RIVM) · 1 drug in this class
10. The Affiliated Hospital of Qingdao University · 1 drug in this class